Background-Peroxisome proliferator-activated receptor-␥ (PPAR␥) is expressed in atherosclerotic plaques and in endothelial cells. The possible effects of PPAR␥ activators on endothelial activation and inflammatory response within the plaque are currently unknown. Methods and Results-We tested the hypothesis that PPAR␥ activators inhibit vascular cell adhesion molecule and intercellular adhesion molecule (ICAM-1) expression in cultured endothelial cells (evaluated by flow cytometry) and homing of monocyte/macrophages to atherosclerotic plaques in vivo. In endothelial cells, the PPAR␥ agonists troglitazone at 100 mol/L and 15-deoxy-⌬12,14 -prostaglandin J 2 (15d-PGJ2) at 20 mol/L markedly attenuated the tumor necrosis factor-induced expression of VCAM-1 and ICAM-1. A significant inhibition of VCAM-1 expression was also evident at 5 and 10 mol/L 15d-PGJ2 and 20 mol/L troglitazone. Expression of E-selectin and PECAM-1 was not altered. To confirm the biological relevance of these results, we assessed the effects of troglitazone on monocyte/macrophage homing to atherosclerotic plaques in apoE-deficient mice. A 7-day treatment with troglitazone (400 mg/kg) significantly reduced monocyte/macrophage homing to atherosclerotic plaques (236Ϯ77 versus 177Ϯ43 macrophages, Pϭ0.03); an even more striking inhibition was found at 3200 mg/kg troglitazone (344Ϯ76 versus 172Ϯ83 macrophages, Pϭ0.005). 
xperimental and pathological studies have suggested that the peroxisome proliferator-activated receptor-␥ (PPAR␥) may have a role in the pathogenesis of atherosclerosis. 1 PPAR␥ is a nuclear receptor highly expressed in several tissues, including adipose tissue, monocytes/macrophages, and smooth muscle cells. 2 In atherosclerotic plaques, PPAR␥ is expressed by macrophage/foam cells, and activation of this receptor can inhibit macrophage activation. 3, 4 Although PPAR␥ is also expressed by endothelial cells, 5 the possible effects of PPAR␥ activators in atherosclerotic plaques are currently unknown.
Expression of adhesion molecules by endothelial cells and adhesion of leukocytes to endothelial cells is an essential step in atherogenesis. 6, 7 We have recently shown, in an animal model of atherosclerosis, that monocyte/macrophage homing to atherosclerotic plaques depends on the expression of the adhesion molecules vascular cell adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1). 8 The aim of our study was to assess the effects of PPAR␥ activators on the expression of adhesion molecules on activated endothelial cells and on monocyte/macrophage homing to atherosclerotic plaques in vivo.
Methods

Cell Cultures
Human umbilical vein endothelial cells (HUVECs, Cascade Biology) were grown in M199 medium with 15% FBS, 0.2 mg/mL heparin, 0.1 mg/mL endothelial cell growth supplement (Biomedical Technologies), 2 mmol/L L-glutamine, and 1% penicillin/streptomycin. Cells were used at passage 2 to 4. Viability by trypan blue exclusion was Ͼ95% in each experiment. Apoptosis was assessed by detection of fragmented DNA at flow cytometry after staining with propidium iodide, according to a previously published protocol. 9 Mouse RAW 264.7 cells were grown in DMEM with 10% FBS, 2 mmol/L L-glutamine, and 1% penicillin/streptomycin.
Detection of Adhesion Molecules
HUVECs were pretreated with the PPAR␥ agonists troglitazone (Parke-Davis), ciglitazone (Biomol), 15-deoxy-⌬12, 14 -prostaglandin J 2 (15d-PGJ2, from Calbiochem); with the PPAR␣ agonist fenofibrate (Sigma); or with vehicle (0.1% DMSO) at the concentrations indicated. After 2 hours, the cells were incubated with tumor necrosis factor (TNF)-␣ at 10 ng/mL for 12 hours. Cells were detached with 10 mmol/L EDTA in PBS (without trypsin) and stained with R-phycoerythrin-labeled monoclonal antibodies (Pharmingen) against VCAM-1 (CD106), ICAM-1 (CD54), or PECAM-1 (CD31) with FITC-labeled monoclonal antibodies (R and D) against E-selectin (CD62E) or with the appropriate isotype IgG (phycoerythrin or FITC) as control. Fluorescence intensity of 9000 cells for each sample was quantified by a FACSCalibur analyzer (BectonDickinson). All experiments were performed in triplicate.
Monocyte/Macrophage Homing to Atherosclerotic Plaques
Monocyte/macrophage homing to the atherosclerotic plaques in vivo was assessed according to a previously published protocol, 8 modified to use a RAW murine macrophage cell line rather than activated peritoneal macrophages. RAW 267.4 cells were incubated for 75 minutes with 2-m fluorescent microspheres (Molecular Probes). Cells were then injected into the tail vein of apoE knockout mice (10ϫ10 6 cells per mouse). 8 The mice were euthanized after 48 hours. Labeled cells adhering to or present inside the atheromatous plaque were quantified in 200 serial sections covering the first 1 mm of the ascending aorta. To validate RAW cells as monocyte/macrophage surrogates in our animal model, we performed an inhibition experiment by pretreating apoE-deficient mice with monoclonal antibody against integrin-␣4 (R1-2, from Pharmingen) 6 hours before injection with RAW cells.
Mice (6 to 8 in each group) were randomized to troglitazone administered by gavage (0.5-mL suspension in water 2 times per day) or to vehicle for 7 days before monocyte/macrophage injection and for the following 2 days. Two different doses of troglitazone (400 mg ⅐ kg
were tested in 2 studies.
Statistics
Results are expressed as meanϮSD. Monocyte/macrophage homing was analyzed with the Mann-Whitney U test to take into account the small sample size. A value of PϽ0.05 (2-tailed) was considered significant.
Results
Expression of Adhesion Molecules
HUVECs showed expression of PECAM-1, low expression of ICAM-1, and no detectable VCAM-1 or E-selectin ( Figure  1 ). Treatment with 100 mol/L of either troglitazone or ciglitazone and 20 mol/L of 15d-PGJ2 did not induce apoptosis (apoptotic cells Ͻ2% in any condition) and did not change baseline expression of adhesion molecules (data not shown). As shown in Figure 1 , incubation with TNF-␣ 10 ng/mL for 12 hours significantly increased the expression of ICAM-1 (A and B), VCAM-1 (C and D), and E-selectin (E and F), with no change in the expression of PECAM-1 (G and H). Pretreatment with troglitazone at 100 mol/L and with 15d-PGJ2 20 mol/L decreased the expression of both ICAM-1 (A and B) and VCAM-1 (C and D) almost to baseline levels. In addition, ciglitazone 100 mol/L (L) decreased expression of VCAM-1 (but not ICAM-1), with an even stronger effect at 200 mol/L (M). A significant reduction of VCAM-1 expression was also evident with 20 mol/L of troglitazone (O) and with 5 or 10 mol/L of 15d-PGJ2 (P and Q), although these doses did not significantly change expression of ICAM-1 (data not shown).
Expression of E-selectin (E and F) or PECAM-1 (G and H) was not changed. The PPAR␣ agonist fenofibrate at 100 mol/L was associated with a slight reduction of VCAM-1 expression after TNF-␣ stimulation (J) but did not change the expression of ICAM-1 (I) or E-selectin (data not shown). Other prostaglandins (PGE 2 20 mol/L and PGF 2␣ 20 mol/L) did not change expression of adhesion molecules (data not shown).
Monocyte/Macrophage Homing
Labeled RAW cells migrated to atherosclerotic plaque, and anti-␣4 antibodies markedly inhibited this phenomenon (Figure 2) . Pretreatment with troglitazone at 400 mg ⅐ kg Ϫ1 ⅐ d
Ϫ1
for 7 days reduced homing of labeled monocyte/macrophages to atherosclerotic plaques in the aortic root significantly, by 25% (Pϭ0.03, Figure 2 ). High-dose troglitazone (3200 mg ⅐ kg Ϫ1 ⅐ d
) was associated with a 50% reduction of monocyte/ macrophage homing (Pϭ0.005). Troglitazone treatment did not change serum levels of total cholesterol, triglycerides, or glucose.
Discussion
The present study shows that PPAR␥ activators markedly decrease expression of adhesion molecules in activated human endothelial cells. Short-term treatment with the PPAR␥ activator troglitazone also significantly inhibits macrophage homing to atherosclerotic plaques.
PPAR␥ is expressed in atherosclerotic plaques, and activation of PPAR␥ inhibits macrophage activation. 3, 4 The antidiabetic drugs thiazolidinediones are specific activators of PPAR␥, whereas the natural agonists are still largely unknown. However, natural polyunsaturated fatty acids can activate PPAR␥, and 15d-PGJ2 is the most specific (K D ϭ2.5 mol/L). 10 PPAR␥ is expressed by human endothelial cells, including HUVECs. 5 Activation of this receptor can inhibit endothelial cell proliferation and may modulate PAI-1 expression, 5, 11 reduce endothelin-1 production, 12 and induce apoptosis, 13 in particular in serum-free conditions. Activation of PPAR␥ results in inhibition of the AP-1 and NF-B pathways 3, 12 that regulate the expression of adhesion molecules by activated endothelial cells. We found that several PPAR␥ activators inhibit expression of ICAM-1 and VCAM-1 in activated HUVECs. However, as in several previous studies, 3,4 the response to troglitazone and ciglitazone occurred at concentrations higher than their binding affinity for PPAR␥, whereas the effects of 15d-PGJ2 were in a concentration range compatible with its K D . The reasons for this discrepancy are unclear, and activation of additional pathways cannot be excluded. However, in a recent study using endothelial cells in conditions similar to our experiments (with complete medium including serum), only high concentrations (100 mol/L) of ciglitazone could activate a PPAR reporter. 13 Thus, it appears that high concentrations of thiazolidinediones are necessary to activate the PPAR␥ receptor in our experimental conditions. Although high concentrations of troglitazone and 15d-PGJ2 (but not of ciglitazone) may also activate PPAR␣, this is unlikely to explain our results, because 5 mol/L 15d-PGJ2 and 100 mol/L ciglitazone are not associated with any PPAR␣ activation. 14 Marx et al 15 recently reported that PPAR␣ activators reduced expression of VCAM-1 (but not ICAM-1 and 
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E-selectin) by activated human saphenous vein endothelial cells. 15 The same study did not find any significant effect of PPAR␥ agonists (troglitazone or 15d-PGJ2 10 mol/L) on the expression of adhesion molecules. Differences in the study design (2-hour pretreatment in our study versus 24-hour) may explain their negative results, because we found that inhibition of VCAM-1 expression by PPAR␥ agonists was much less evident with 24-hour pretreatment than with a 2-hour pretreatment (data not shown).
We reported previously that in apoE-deficient mice, homing of activated peritoneal macrophages to atherosclerotic plaques is reduced by pretreatment with monoclonal antibodies against ICAM-1 and ␣4 integrin (the natural ligand for VCAM-1). 8 We modified this model to use a mouse macrophage cell line (RAW 267.4) that does not express significant levels of PPAR␥. 3 Troglitazone treatment significantly inhibits monocyte/macrophage homing, with a 50% reduction at the highest dose. However, 400 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 of troglitazone, a dose used in mouse models of diabetes, 16 is also associated with a significant reduction in monocyte/macrophage accumulation. Similarly, troglitazone inhibits neointimal hyperplasia in rats. 17 Troglitazone also has antioxidant effects, and the beneficial effects observed in our experiments may not be due only to PPAR␥ activation.
PPAR␥ activators are used in treatment of type II diabetes, and in a preliminary study, treatment with troglitazone was found to reduce carotid intimal-medial thickness, a marker of early stages of atherosclerosis. 18 However, atherosclerosis is a composite phenomenon involving many different molecular pathways, and further studies are needed to assess the effects of PPAR␥ activators on the progression of atherosclerosis. 
